September 27, 2016
Holding Companies Report - MAKOR'S monitor
Key highlights from the past two weeks:
• PARGESA /GBL - the redemption of the EUR 250m BNP exchangeable bond is due to expire this week. Following that we expect the selling pressure on Pargesa to significantly moderate and we see the current level of the spread as a buying opportunity- see more details next page.
• Wendel (MF: FP) – the company continues to increase its exposure to African growth. Management announced last week it will acquire Tsebo Solutions, a South African pan leader in facilities management. Prior to this deal Wendel already had presence in Africa with its stake in IHS, Saham Group and its recent investment in SGI (commercial real Estate assets in Africa). The discount is now approx. 30% in line with the past year average.
• Eurazeo (RF FP) sold last week 6% of its stake (15m shares) in Moncler for €230m (net proceeds of €190m). In addition, Credit Agricole, which owns 14.9% of Eurazeo, issued today €300m exchangeable bonds for Eurazeo shares (to replace the exchangeable zero coupon bonds it issued in 2013 and due in 2016), at a premium of 27.5%-32.5% due in 2019. Discount is ~26% - slightly above the last year average.
Makor Capital
11 Menachem Begin St., 26th FL
Ramat Gan 52681
ISRAEL
Tel +972 3 5453 762Fax +972 3 7162 680
Research Disclaimer
This publication has been prepared by Makor Capital Limited (“Makor Capital”) and is intended for professional or qualified investors only. Makor Securities London Ltd (“Makor Securities”)is distributing this material to its clients who are Eligible Counterparties or Professional Clients under FCA Rules. It may also be disseminated to persons who are Investment Professionals within the meaning of the Financial Services and Markets Act 2000 (Financial Promotion Order 2005). In the United States, Makor Capital only distributes this material to major US institutional investors (as that term is defined in Rule 15a-6 of the Securities and Exchange Act of 1934) and to SEC-registered broker-dealers or banks acting in a broker–dealer capacity. This material is not intended for distribution to any other persons and should not be redistributed. If you do not fall into any of these categories you should disregard it.
This material is a marketing communication. It is not investment research and has not been prepared in accordance with legal requirements designed to promote the independence of investment research. It is not subject to any prohibition on dealing ahead of the dissemination of investment research under U.K. law. This material is not a research report and is not intended to be a research report as defined under U.S. securities laws and regulations. This material is not intended to provide information reasonably sufficient upon which to base any investment decision.
This material does not take into account the particular investment objectives, financial situation or needs of individual clients or other recipients. Before acting on this material, clients and other recipients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.
This material should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action.
In the United States, Makor Capital does not offer securities services to U.S. persons except pursuant to SEC Rule 15a-6 only to major US institutional investors and SEC registered broker-dealers or banks acting in a broker–dealer capacity. Transactions in the United States must be effected through the U.S. broker-dealer, Oscar Gruss & Son Incorporated. Oscar Gruss & Son has not prepared, reviewed or distributed this material.
Some of this material is produced by providers which Makor Securities believes to be reliable, but Makor Securities does not warrant or represent (expressly or impliedly) that it is accurate, complete, not misleading or as to its fitness for the purpose intended and it should not be relied upon as such.
Opinions expressed will be the current opinions of those producing this material as of the date appearing on this material only. We expect those producing the material in this publication to update it on a timely basis but can give no undertaking that they will do so and regulatory compliance or other reasons may prevent them from doing so (or us from disseminating updated material).
Members and employees of Makor Securities London Ltd, employees of Makor Capital, Makor Capital Markets may from time to time have long or short positions in securities, warrants, futures, options, derivatives or other financial instruments referred to in this material. For Makor Securities, this information is set out in our Conflicts of Interest Policy which is available on request. Policies for the production of research from other research providers are available on request. Unless otherwise stated, share prices provided within this material are as at the close of business on the day prior to the date of the material.
Neither the whole nor any part of this material may be duplicated in any form or by any means. Neither should any of this material be redistributed or disclosed to anyone without prior consent. This material is issued for general information and discussion purposes only. None of Makor Securities, Makor Capital, Makor Capital Markets accepts liability whatsoever for any direct, indirect or consequential loss or damage of any kind arising out of the use of all or any of this material.
The services, securities and investments discussed in this material may not be available to, nor are suitable for all investors. Investors should make their own investment decisions based upon their own financial objectives and financial resources and it should be noted that investment involves risk, including the risk of capital loss. Past performance is no guide to future performance. In relation to securities denominated in foreign currency, movements in exchange rates will have an effect on the value, either favourable or unfavourable.
All investors. Investors should make their own investment decisions based upon their own financial objectives and financial resources and it should be noted that investment involves risk, including the risk of capital loss. Past performance is no guide to future performance. In relation to securities denominated in foreign currency, movements in exchange rates will have an effect on the value, either favourable or unfavourable.
Entities
Makor Securities London Ltd is authorised and regulated by the Financial Conduct
Authority (FCA registration number 625054)
Makor Capital, company number 514456466, is incorporated in Israel and is a 100% held
subsidiary of Makor Holdings Pte Ltd incorporated in Singapore.
Makor Capital Markets SA, company number CH-660.2.999.011-0 is incorporated in Switzerland
and is also a 100% held subsidiary of Makor Holdings Pte Ltd.
Having trouble viewing this email? Click here
lchekroun@makor-cm.comThis email was sent to by Research@Makor-Capital.com
V.I.Plus e-mail marketing
In reaction to disappointing earnings/guidance: FDS -0.7%
M&A news:
- SXL -8.2% (to acquire Vitol's crude platform for about $760 mln plus working capital; commenced an underwritten public offering of 21 mln common units pursuant to an effective shelf registration statement on Form S-3 previously filed with the SEC)
- RICE -6% (to acquire Vantage Energy for approximately $2.7 billion; commences a 40 mln share underwritten public offering of common stock)
- MPW -3.9% (to acquire the real estate interests of nine acute care hospitals operated by Steward Health Care System; commences 33.5 mln common stock offering)
Select oil/gas related names showing early weakness: MRO -2.5%, WLL -2.5%, CHK -2.1%, OAS -1.9%, RIG -1.8%,RDS.A -1.2%
Other news:
- CVM -44.4% (receives FDA notice that its Multikine Phase 3 trial placed on clinical holdg)
- MIME -8.7% (commences a registered secondary public offering of 4 mln ordinary shares by selling shareholders)
- CZR -7.5% (announce proposed consensual restructuring plan for CEOC)
- NAT -7.1% (announced an underwritten public offering of 11 mln common shares)
- MYOK -3.7% (announces underwritten public offering of 3,800,000 shares of its common stock)
- AMGN -2.1% (reports Phase 3 KYPROLIS; trial did not meet the primary endpoint)
- GILD -1.4% (downgraded to Mkt Perform from Outperform at Leerink Partners)
- DLTR -0.9% (downgraded to Underweight from Neutral at Atlantic Equities)
- CRI -0.8% (downgraded to Market Perform from Outperform at Wells Fargo)
- SJM -0.5% (downgraded to Neutral from Outperform at Credit Suisse)
In reaction to strong earnings/guidance: SNX +7.8%, ( also increased quarterly cash dividend), THO +1.3%, .
M&A news:
- GI +88.9% (to be acquired by Boston Scientific (BSX) for $8.00/share)
- RMP +2.8% (ticking higher, will purchase the acquired midstream assets from Rice Energy for $600 mln. The transaction is expected to close in the fourth quarter of 2016, subject to customary closing conditions)
- INFI +12.4% (presents new preclinical data for IPI-549 that "appear favorable")
- KITE +11.9% (announces positive topline KTE-C19 data from ZUMA-1 pivotal trial in patients with aggressive non-hodgkin lymphoma (NHL) -- Study met primary endpoint with combined complete response rate of 39% at three months)
- ARRY +11.2% (cont strength)
- PPHM +10.2% (presentation of preclinical study data demonstrating that PS-targeting antibodies similar to bavituximab)
- PIRS +10.1% (Pieris Pharmaceuticals presents 'positive' data for its bispecific drug candidate, PRS-343)
- NYRT +8.2% (files for 3,452,7 share common stock offering by selling shareholders; retains Spencer Stuart for independent Board Of Directors candidate search)
- PERI +8% (CEO to step down; Directors to begin search for new CEO)
- JUNO +6.7% (following KITE's CAR-T data)
- DNAI +5.9% (obtains an exclusive license from the CRT Pioneer Fund LP for worldwide rights to develop and commercialize PNT737)
- ATNM +5% (initiates a Phase 2 clinical trial of Actimab-A in patients newly diagnosed with Acute Myeloid Leukemia who are over the age of 60)
- BLDP +4.9% (announces that automotive OEM Audi AG has issued purchase orders to accelerate certain key development activities)
- HEAR +4.3% (light volume, restructuring Hypersound business to substantially lower operating costs)
- NAVB +4.1% (appoints Michael Goldberg, M.D. President and Chief Executive Officer and Eric Rowinsky, M.D. as Chairman)
- PTIE +3.8% (after Monday's 50% decline on CRL news)
- DRRX +2.6% (after Monday's 30%+ decline on CRL news)
- AGRO +2.4% (Adecoagro S.A. extends share repurchase program for and additional twelve-month period ending on September 23, 2017)
- TRIL +1.3% (presents data indicating TTI-621 signal leads to enhanced anti-tumor CD8 + T cell responses)
- NQ +1% (announces Zhongzhi Hitech Overseas Investment agreed to purchase $220 mln convertible notes through a private placement)
- ORAN +2.2% (upgraded to Outperform from Neutral at Credit Suisse)
- LLY +1.5% (upgraded to Buy from Neutral at Goldman)
- AZO +1.2% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- AMZN +0.6% (target raised to $1000 from $925 at JP Morgan)
- CBOE +0.6% (upgraded to Neutral from Underperform at Credit Suisse)
Gapping down: SXL -7.1%, NAT -6.8%, RICE -5.3%, MIME -5.1%, MYOK -3.7%, MPW -3.5%, RBS -3.3%, DB -3.2%, CS -3%,CF -1.6%, GILD -1.3%, QGEN -1.2%, MT -1%, AZN -1%, FCX -1%, NVO -0.9%, FDS -0.8%, SLB -0.7%, RDS.A -0.6%, AMGN-0.5%